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the U.S. Health Examination Survey. The survey population comprised 6768 youths, aged 12 to 17 years, selected to represent the U.S. population with r?spect to age, sex, race, and demographic status. Serum urate increases markedly during pubescence in males; in females the increase is modest. In males, the increase is strongly associated with sexual maturation (Tanner staging) and with skeletal age (radiographic assessment). The relationships among skeletal age, serum urate, and Tanner stage in males are strong enough to permit use of urate concentration in assessing sexual and physiological maturation. In later dolescence, body composition (body mass index and skinfold hickness), and hematocrit are more closely related to serum Jrate than is sexual maturation. Blood pressure and serum cholesterol have significant but weaker relationships. These relationships are similar to those in adults. Serum urate concentrations are 0.5 mg/dl lower in black male and female youths of all ages, and this consistent difference is unrelated to 3ther factors. During adolescence, the early rise in serum urate concentration is related to physiological maturation, while the levels in late adolescence are similar to those in adults. We performed chest x-rays, electrocardiograms (ECGs), and echocardiograms (ECHOs) on 35 hypertensive and 35 normotensive subjects 14-16 years of age who were matched for age, race, sex, and body size (ponderal index). All hypertensive patients had elevation of systolic and/or diastolic blood pressure at or above the 95th percentile for age on 3 consecutive examinations. No patient in either group showed cardiomegaly on chest x-ray. Five hypertensive patients ( 1 4 ' ) and 7 control subjects (20%) had ECG criteria for LVH, indicating no significant difference between the groups. Analysis of ECHOs showed the mean left ventricular wall thickness (LVT) in hypertensives was 7.8mm+0.87 (SD), compared with 6.5mm+0.81 in the controls. Left ventrTcular mass indexed to body-surface area (LVM/BSA) averaged 8 2 5 5 and 7 0 5 5 respectively. LVT was then also indexed to BSA and using our control data we defined the upper limits of normal in terms of the 90th percentile values: for LVT/BSA this was 0.470, and for LVM/BSA this was 100. Of hypertensive patients, 23% had LVTIBSA above the 90th percentile and 17% had LVM/BSA, above this level. For controls, only 3% had elevated LVT/BSA, and 6% had elevated LVM/BSA. m e s e findings suggest that ECHO may be a more useful method than either chest x-ray or ECG to detect LVH in hypertensive adolescents.
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In adolescent girls, secondary amenorrhea can result from a variety of physiologic and psychologic disturbances. Previous reports associating amenorrhea and primary hypothyroidism have not distinguished between the alternative etiologic roles of thyroxine deficiency and hyperprolactinemia.
We have evaluated two girls with secondary amenorrhea who had clinical and chemical evidence of hypothyroidism. Both had low basal Tq's (0.8 and 3.8 pg%), calculated free Tq's (0.1 and 0.7 pg%), and ~~l . 5 (51 and 81 ng%). Both had undetectable basal TSH with normal TSH response to TRH. Basal FSH and LH were normal, as was the response to LHRH. Basal prolactins were 6 and 14 nglml, and both girls had growth hormone responses of 115 ng/ml in response to insulin-induced hypoglycemia. Pituitaryadrenal function and reserve were also normal. In neither case were there any historical, physical, or laboratory features compatible with anorexia nervosa. After treatment with 1-thyroxine, both girls had a resumption in menses.
These two adolescent girls thus appear to have isolated hypothalamic hypothyroidism. The associated secondary amenorrhea demonstrates that thyroid deficiency alone, without hyperprolactinemia, can interfere with normal hypothalamic-pituitaryovarian function. We have studied the ratio of bioactive to immunoactive (B/I) luteinizing hormone (LH) in eight girls with gonadal dysgenesis before and after estrogen replacement therapy with low doses of oral ethinyl estradiol. The estrogen suppression of bioactive LH, as measured by a rat interstitial cell testosterone assay (RICT), was more profound than the suppression of radinimn~t~no-assayable (RIA) LH in five girls who had elevated basal serum LH levels: The B/I before therapy was significantly higher (p<0.005) at 2.78t0.12 (n=6) than after three months of 10 ug of ethinyl estradiol (1.44+0.11, n=S), and after three suhsequent months of 20 ug of ethinyl estradiol (0.60+0.08, n=3). In two younger patients without elevated basal RIA 111, however, the B/I was low. Estradiol 17-8 in concentrations of 0.1, 5 and 10 ng/ml had no effect on testosterone production in the RICT assay.
These data suggest that estrogen affects the qualitative form as well as the quantitative amount of LH secreted, possibly via a structural change in the LH molecule, or by inhibition of another substance with LH-like bioactivity, or by other mechanisms as yet undefined.
